tbuckley/cabot-search huggingface dataset:
Abstract P5-11-13: Experience in the ABC Medical Center of Mexico City 2010-2015 using scalp-cooling system (DigniCap) for prevention of alopecia induced by chemotherapy
Authors: RE Hernandez, R Gerson, G Olivares, S Rivera, A Serrano, A Villalobos, M Lazaro
Journal: Cancer Research (2017)

Abstract Background: Alopecia is one of the secondary side effect whit the most emotionally impact for patients undergoing chemotherapy (CTX) The DigniCap System is the first scalp cooling system use to minimize alopecia. Methods: The objetive of this study was to evaluate in a restrospective trial the efficacy of DigniCap preventing alopecia in consecutive patients treated in ABC Medical Center from December 2010 to January 2015. Patients recieve different chemotherapy regimens, with different modalities, neo , adyuvant and for metastases in first and second line, as in many clinical stages whit breast cancer (BC), were evaluated with the visual scale of Dean (score 0: 0-25%, 1: 25-50%, 2: 50-75%, 3: 75-100%) with photographs of the before and after treatment. Results: 120 pts with BC in stages I-V were treated with a taxane and antraciclins regimen of chemotherapy, 66 pts receive 12 treatment weekly of paclitaxe (T)l and 4 adriamicin/cyclophosphamida (AC) every 21 days, 28 pts 6-8 cycles every 21 days AC-Taxol, 22 pts (18%)suspended the treatment because of the loss of more than 50% of hair at the 2nd an 3rd chemotherapy cycle. 98 pts actually finished the treatment (72%). Of these, 82 pts (84%) no had or had a minimal loss of hair (Dean score 0-1), 16 pts (16%) had a 50% of hair loss (Dean score 3). 8pts recieve more than one regimen of chemotherapy. In the tracing any metastases or side effects were presented with the use of DigniCap. Conclusions: The use of DigniCap minimize alopecia in a 84%, including pts with more than one chemotherapy regimen, in a a safety level. Citation Format: Hernandez RE, Gerson R, Olivares G, Rivera S, Serrano A, Villalobos A, Lazaro M. Experience in the ABC Medical Center of Mexico City 2010-2015 using scalp-cooling system (DigniCap) for prevention of alopecia induced by chemotherapy [abstract]. In: Proceedings of the 2016 San Antonio Breast Cancer Symposium; 2016 Dec 6-10; San Antonio, TX. Philadelphia (PA): AACR; Cancer Res 2017;77(4 Suppl):Abstract nr P5-11-13.
LSC 2011 Abstract: Effect of inhaled apocynin on reactive oxygen species concentrations in exhaled breath condensate of asthmatics
Authors: Joanna Stefanska, Agata Sarniak, Anna Wlodarczyk, Milena Sokolowska, Zbigniew Doniec, Dariusz Nowak, Rafal Pawliczak
Journal: European Respiratory Journal (2011)

Reactive oxygen species (ROS) have a strong impact on homeostasis and are thought to play an important role in inflammation in asthma. The sources of oxidative stress in patients with chronic inflammatory lung diseases derive mainly from increased amounts of ROS and reactive nitrogen species (NOS), generated by airway cells. Apocynin is and agent which blocks NADPH oxidase - the enzyme, responsible for ROS production. The anti-inflammatory activity of apocynin has been demonstrated in a variety of cells and animal models of inflammation. Therefore, considering apocynin activities, we investigated the effect of nebulized apocynin in 14 nonsmoking asthmatics, in placebo-controlled,  cross-over  design study. Effects of apocynin have been checked 30, 60 and 120 minutes after nebulization by collecting exhaled breath condensate (EBC) samples. Additionally, we investigated safety parameters.  Apocynin significantly decreased H 2 O 2  concentration in EBC in comparison to placebo after 60 and 120 min. (0.29 μM  vs . 0.44 μM, and 0.27 μM  vs . 0.4 μM, respectively). Moreover, apocynin significantly reduced NO 2  -  concentration 30 and 60 min after nebulization (2.75 μM  vs . 4.65 μM, and 2.5 μM  vs . 4.05 μM, respectively) in comparison to placebo. Finally, apocynin caused a significant decrease of NO 3  -  concentration in EBC after 60 and 120 min after administration, comparing to placebo (5.34 μM  vs . 8.2 μM (60 min), and 5.3 μM  vs . 8 μM, (120 min) respectively). No influence of apocynin on safety parameters, and no adverse effects has been observed.  These data suggest that using apocynin might be a promising solution to alleviate inflammatory process, and probably, symptoms of inflammatory diseases.
Platinum-based combination therapy (PCT) and outcomes for patients (pts) with mixed hepatocellular carcinoma and intrahepatic cholangiocarcinoma (mHCC/ICC).
Authors: Louise Catherine Connell, James J. Harding, Maeve Aine Lowery, Nancy E. Kemeny, Andrea Cercek, Marwa I Abdelgawad, Eileen Mary O'Reilly, Leonard Saltz, Ghassan K. Abou-Alfa
Journal: Journal of Clinical Oncology (2015)

e15146 Background: mHCC/IHC is a histologic subtype of liver cancer for which there are no established therapies. Major clinical trials of either HCC or ICC have excluded such pts and only case reports are available to guide clinicians on treatment options. Methods: Cases of histologically confirmed mHCC/ICC were identified and reviewed from 1994 to 2014 at a single institution. Clinicopathologic parameters, treatment course, outcomes, and genotype by 341 gene sequencing (MSK-IMPACT) were obtained. Survival estimates were made by by Kaplan-Meier methodology. Results: 39 cases of recurrent unresectable or metastatic mHCC/IHC were identified. This averages 5% of all HCC cases seen yearly at MSKCC. Pts had a median age 59 years (range 35-79); male (64%); HBV positive (23%), HCV positive (21%); Child Pugh A (54%), B (16%), and not reported (31%). Metastatic disease predominated (37/39 pts). Prior therapies included surgical resection (43.6%) and/or locoregional approaches (35.9%). In 28 pts, first-line systemic therapy included: gemcitabine or 5-fluorourcil monotherapy (5), PCT (12), sorafenib (8), or clinical trials (3). 6 pts that received PCT also received sorafenib. The median AFP and CA19-9 were 1214.2 (1.6-63,224.1) and 199 (1-1562), respectively. The median PFS and OS from time of first systemic treatment were 2.37 and 10 months, respectively. The median PFS for monotherapy, sorafenib, PCT, and PCT + sorafenib were 1.8, 3.1, 4.5, and 8.2 months, respectively (log rank p = 0.16). Overall survival favored PCT + sorafenib with median OS of 1.8, 7.6, 8.4, and 14.7 months (Log rank p = 0.01), respectively. Three tumors tested so far using MSK-IMPACT showed alterations in TP53, JUN, PTEN, RB1, SETD2, SPEN, TSC2, KDM5C, NOTCH1, NOTCH4 and TSHR. Conclusions: mHCC/ICC pts perform similarly to historic controls of pure ICC when treated with PCT. The addition of sorafenib to PCT should be explored in specific clinical trials for this population.
Abstract P5-11-05: Examining bone degeneration as a side effect of treatment in premenopausal breast cancer patients
Authors: M Kim, HJ Kim
Journal: Cancer Research (2017)

Abstract Background: Although it is widely known that adjuvant treatments cause osteoporosis in postmenopausal women, the effect of treatment and the exact degree of bone loss in premenopausal women is not well understood. For this reason, this study examined the relationship between the changes of bone mineral density(BMD) and the types of treatment in premenopausal breast cancer patients. Method: This retrospective study looks at preoperative and annual spine bone densitometry tests conducted on breast cancer patients during their observational period following initial treatment for their diagnosis. 461 premenopausal patients who received treatment from January 2006 to April 2007 were the study cohort because of the availability of bone mineral density (BMD) data (L-spine and femur T scores) for a two-year period. The data from the patients were separated into groups according to their treatment plans: observation, adjuvant chemotherapy, adjuvant chemotherapy followed by use of Tamoxifen, and GnRHa(Gonadotropin Releasing Hormone agonist) followed by Tamoxifen. Results: Of the 461 patients, 21 received no treatment aside from surgery, 75 received only Tamoxifen, 34 only chemotherapy, 166 chemotherapy and Tamoxifen, and 165 Zoladex and Tamoxifen. The no treatment group demonstrates the standard annual change in BMD. At first year, the chemotherapy only group and tamoxifen after chemotherapy group showed significant bone loss in the first year (p&amp;lt;0.005, both). The patients who received tamoxifen alone or tamoxifen with goserelin showed decrease BMD but not significant. After 2 years, tamoxifen with goserelin group showed significant decreased BMD in both spine and femur (p&amp;lt;0.001, p=0.001, both). Chemotherapy group showed partial recovery from the first year bone loss. Conclusion: The patients who received chemotherapy or GnRHa as treatment showed the greatest degree of bone degeneration but at different periods. However, Tamoxifen used along with these treatments seemed to lessen the extent of bone degeneration. Significant bone loss from hormone treatment occurred two years after surgery as compared to one year for chemotherapy. Citation Format: Kim M, Kim HJ. Examining bone degeneration as a side effect of treatment in premenopausal breast cancer patients [abstract]. In: Proceedings of the 2016 San Antonio Breast Cancer Symposium; 2016 Dec 6-10; San Antonio, TX. Philadelphia (PA): AACR; Cancer Res 2017;77(4 Suppl):Abstract nr P5-11-05.
Efficacy of antireflux cuff after laparoscopic Heller myotomyin the treatment of achalasia
Authors: Zdeněk Kala, Filip Marek, Vladimír Procházka, Jiří Dolina, Radek Kroupa
Journal: Gut (2008)

Our sugical results and postoperative follow-up show that
laparoscopic Heller myotomy with Toupet partial fundoplication
is a safe end effective way of treatment and can be recommended
as a method of first choice
BRCA1-like copy number profiles to predict benefit of high-dose alkylating chemotherapy in high-risk breast cancer (BC): Results from randomized WSG AM-01 trial.
Authors: Philip C. Schouten, Oleg Gluz, Nadia Harbeck, Svjetlana Mohrmann, Raihana Diallo-Danebrock, Enrico Pelz, Janneke Kruizinga, Arno Velds, Marja Nieuwland, Ron M. Kerkhoven, Cornelia Liedtke, Markus Frick, Ronald Kates, Sabine C. Linn, Ulrike Nitz, Frederik Marme
Journal: Journal of Clinical Oncology (2014)

11018 Background: DNA copy number profiles identify patients with a defect in BRCA1 associated with a homologous recombination DNA repair defect. We previously showed that patients with a BRCA1-like profile benefit from high-dose (HD) and tandem HD chemotherapy (CT) (carboplatin/thiotepa/cyclophosphamide; ifosfamide/epirubicin/carboplatin). WSG AM-01 trial reported superiority of tandem HD vs. dose-dense CT in high-risk BC patients. Subgroup analysis attributed this effect to triple-negative BC. Methods: Phase III WSG AM-01 trial randomized 403 patients with >9 positive lymph nodes to 2xEC q2w followed by tandem HD (epirubicin/cyclophosphamide, thiotepa) or DD 4xEC --> 3xCMF q2w CT. Tumor CN profiles from 98 patients were generated with high-throughput sequencing and classified as BRCA1-like or non-BRCA1-like. Correlations with prognostic factors were assessed and Cox regression was done to investigate predictive/prognostic impact of BRCA1-like status on event free survival (EFS). Results: 17 of 94 (18%; HD/DD: 10 (19%)/7 (17%)) patients had BRCA1-like profiles. BRCA1-like status associated with high tumor grade (p=0.005) and triple-negative status (p<0.001). In multivariate Cox analysis for EFS, only age <50 years entered (HR=1.9, p=0.02) as a main effect. In subgroup analysis, only BRCA1-like status predicted for efficacy of HD. HR=0.26 (95% CI: 0.07-0.94, p=0.04) for BRCA1-like vs. 0.76 (95% CI: 0.43-1.34; p: 0.35) for non-BRCA1 like. In exploratory Cox interaction analysis (backward elimination) with BRCA1-like status, therapy and their interaction, the model retained BRCA1 status (HR=2.25; 95% CI: 1.07-5.94) and the predictive interaction BRCA1*therapy (HR=0.22; 95% CI: 0.06-0.79). Conclusions: Retrospective analysis suggests that superiority of rapidly cycled tandem HD alkylating over standard dose-dense CT in high-risk BC is substantially attributable to BRCA1-like (rather than TN) status. Comparing with other studies, this effect seems less drug-specific and indicates rather higher sensitivity of BRCA1-like tumors to any HD alkylating CT. The results will be validated in the prospective WSG ADAPT TN trial.
PP72. IMMUNE INFILTRATION OF TUMOR MICROENVIRONMENT FOLLOWING IMMUNOTHERAPY FOR GLIOBLASTOMA MULTIFORME
Authors: Mr Giannis Sokratous, Mr Stavros Polyzoidis, Prof Keyoumars Ashkan
Journal: Neuro-Oncology (2017)

BACKGROUND: Autologous dendritic cell immunotherapy has been proven effective in treating tumours outside the central nervous system. Current evidence from phase I and II trials suggest a similar efficacy for central nervous system tumours as well and that an active immune response against these tumours can be generated. OBJECTIVE: We aim to review the literature to identify the types of immune responses against gliomas found to be generated by dendritic cell vaccinations and the types of immune cells subsequently infiltrating the glioma microenvironment. METHODS: A systematic review of the literature was performed by searching the online databases PubMEd, Google Scholar, and EMBASE with use of the keywords intratumoral, infiltration, lymphocytic, vaccination and gliomas. RESULTS: Seven studies reporting lymphocytic infiltration of gliomas microenvironment were identified. Three studies (42.8%) reported presence of tumour infiltrating lymphocytes in 50%, 50% and 28.6% of included patients respectively in the post-vaccination specimens that were not present in the pre-vaccination samples. The remaining 4 (57.2%) reported an up to six-fold increase in the number of pre-existing lymphocytes following vaccination. CONCLUSION: Present data indicate that tumour infiltration by lymphocytes can be induced by dendritic cell immunotherapy and that this may positively affect clinical outcome. It still remains unclear which factors influence the above reaction and therefore prediction of response to treatment is still not possible.
Exercise training in interstitial lung disease: lumping or splitting?
Authors: Katrina Curtis, Nicholas S Hopkinson
Journal: Thorax (2017)

In 1952, Alvan Barach, a New York physician, wrote, ‘It may seem unusual perhaps to suggest exercise to these breathless people, but in fact it is one of the ways by which they can restore physical fitness’.1 Since then, pulmonary rehabilitation (PR) has proven its worth as a high-value treatment for COPD,2 improving exercise capacity, quality of life and muscle strength while also reducing hospital admissions.3–6 The usefulness of PR in other respiratory conditions, including interstitial lung disease (ILD), has been assumed because of the shared presence of deconditioning, fatigue, dyspnoea, exercise intolerance and impaired quality of life, factors known to be amenable to exercise training.

ILD includes a heterogeneous group of disorders, with severity and prognosis that vary both between subtypes and at an individual level. The basis of exercise training as a treatment modality may therefore be less straightforward than in other pulmonary disorders. People with COPD often present with a long history of physical inactivity and activity levels are typically reduced even in early disease.7 Patients with ILD may have a shorter period prior to presentation and a more rapid trajectory of lung function decline than other chronic lung conditions with less time for deconditioning to develop. In addition, some will be receiving systemic corticosteroid therapy known to have important effects on muscular function8 and important systemic effects may be present, including rheumatological conditions, direct muscle involvement in connective tissue diseases and pulmonary hypertension limiting cardiac output. These all …
Abstract P3-14-14: Endoscopic 3D latissimus dorsi muscle harvesting for immediate breast reconstruction. Results of our 7 patients experience in Antoine Lacassagne Nice Cancer Center
Authors: E Barranger, M Dejode
Journal: Cancer Research (2017)

Abstract Introduction : The harvest of the latissimus dorsi muscle for the realization of immediate breast reconstruction induces a large dorsal scar measuring up to 20 centimeters, while only the muscle is used. We present here the results of our experience of endoscopic harvesting of the latissimus dorsi muscle using 3D technology. Our main objective is to reduce the dorsal scar and second assess the functional consequences for patients. Methods: Between December 1st, 2015 , and June 1st, 2016, there were 7 patients who underwent latissimus dorsi endoscopic harvesting, with 3D technology, for an immediate breast reconstruction after a skin-sparing or nipple sparing mastectomy. Results: 4 patients had latissimus dorsi muscle with breast implant and 3 patients by latissimus dorsi muscle only. The age average was 55 years (range 45-70). The mean length of surgery was 250 minutes (range 150- 380). The mean length of hospitalization was 7 days (range 4-12 days). One patient treated for local recurrence had skin necrosis because of previous radiotherapy. Donor site seroma was the main post surgery drawback. Patients on average benefited from 3 evacuations (range 1-5) of 850ml (range 640-1270ml). Acceptance of the reconstructed breast was good in six cases, and poor in one case. Only one patient reported discomfort at the donor site 1 month after surgery. Conclusion: The endoscopic 3D latissimus dorsi flap harvesting allows to reduce donor site scar. There is no significant difference concerning complications or post-operative pain and functional discomfort between the endoscopic and classic harvesting procedure. Citation Format: Barranger E, Dejode M. Endoscopic 3D latissimus dorsi muscle harvesting for immediate breast reconstruction. Results of our 7 patients experience in Antoine Lacassagne Nice Cancer Center [abstract]. In: Proceedings of the 2016 San Antonio Breast Cancer Symposium; 2016 Dec 6-10; San Antonio, TX. Philadelphia (PA): AACR; Cancer Res 2017;77(4 Suppl):Abstract nr P3-14-14.
Increasing Grades of Follicular Lymphoma Correlate with Better Prognosis in Patients Treated with Rituximab
Authors: Björn Engelbrekt Wahlin, Christer Sundström, Harald Holte, Birgitta Sander, Bjørn Østenstad, Peter de Nully Brown, Erlend B. Smeland, Jan Delabie, Birger Christensson, Eva Kimby
Journal: Blood (2011)
Poor Performance Status, Chemorefractory Disease At Transplantation, and Umbilical Cord Blood As Donor Source Were Adverse Prognostic Factors for Overall Survival After Allogeneic Stem Cell Transplantation for Follicular Lymphoma: Retrospective Study of the Japan Society of Hematopoietic Stem Cell Transplantation (JSHCT) Lymphoma Working Group
Authors: Koji Izutsu, Ritsuro Suzuki, Shinichi Kako, Rika Sakai, Takehiko Mori, Shingo Yano, Jun Kato, Takahiro Fukuda, Shuichi Taniguchi, Minoko Takanashi, Yasuo Morishima, Junji Tanaka, Junji Suzumiya
Journal: Blood (2011)
A Pooled Analysis of 1,546 Patients with HIV-Associated Lymphoma: Assessment of Lymphoma-, HIV-, and Treatment-Specific Factors On Clinical Outcomes
Authors: Stefan K Barta, Xiaonan Xue, Dan Wang, Roni Tamari, Jeannette Y Lee, Nicolas Mounier, Lawrence D. Kaplan, Josep-Maria Ribera, Michele Spina, Umberto Tirelli, Rudolf Weiss, Lionel Galicier, Francois Boue, Wyndham H. Wilson, Christoph Wyen, Albert Oriol, Jose-Tomas Navarro, Kieron Dunleavy, Richard F Little, Lee Ratner, Olga Garcia, Mireia Morgades, Eric Oksenhendler, Scot Remick, Joseph A Sparano
Journal: Blood (2012)
Optimizing the Outcomes of Allogeneic Hematopoietic Stem Cell (HSC) Transplantation for Hematological Malignancies: The Perfect Combination of Conditioning Regimen, Disease Stage and Type of HSC Donor
Authors: Mauricette Michallet, Mohamad Sobh, Hélène Labussière-wallet, Marie Balsat, Caroline Lejeune, Sophie Ducastelle-Leprêtre, Fiorenza Barraco, Xavier Thomas, Franck E. Nicolini
Journal: Blood (2015)
Distinct Functions of Stat5A and Stat5B in Chronic Myeloid Leukemia (CML): Stat5B Is Implicated in Survival and Self-Renewal and Stat5A in Imatinib Resistance.
Authors: Imen Najjar, Adrien Grimont, Nicolas Martin, Severine Martin-Lanneree, Marie Laure Bonnet, Francois Guilhot, Jean-Claude Chomel, Evelyne Lauret, Ali G. Turhan, Isabelle Dusanter-Fourt
Journal: Blood (2010)
Clinical Significance of Immunohistochemical Markers of Diffuse Large B-Cell Lymphoma In the Rituximab Era.
Authors: Miyuki Hayama, Masataka Okamoto, Yuki Hagiwara, Ken Tanae, Mika Kohri, Naoki Takahashi, Tadashi Yoshino, Koichi Ohshima, Nozomi Niitsu
Journal: Blood (2010)
PP47. TECTAL PLATE GLIOMAS IN ADULTS: NOT SUCH AN INDOLENT TUMOUR
Authors: Mr James Walkden, Dr Emma Cannon, Mr Michael Jenkinson, Mr Andrew Brodbelt, Mr Emmanuel Chavredakis
Journal: Neuro-Oncology (2017)

OBJECTIVE: Tectal gliomas are a rare subset of brainstem gliomas accounting for less than 5% of brainstem tumours in children and 8% in adults. Historically, it has been reported that tectal gliomas are more likely to follow a benign, indolent course than brainstem gliomas. We investigated the clinical history, radiological surveillance and operative management of tectal plate glioma in a large adult series. METHODS: All neuroradiology reports available at our institution from January 2007 to March 2015 were searched using ‘tectal plate’, ‘tectal lesion’ and ‘tectal glioma’ as keywords. Clinical details including presenting history, age, clinical course, neuropathology and any operative interventions were identified from case notes. RESULTS: The keyword search identified 344 reports which were subsequently narrowed to 69 patients with tectal plate tumours. We identified 39 suspected low grade tectal plate gliomas of which 12 had confirmed neuropathology. 7 tectal plate lipomas and 3 non glial tumours involving the tectal plate were identified. Of the 12 patients with proven histology the average age at diagnosis was 24 years with all but 3 presenting with hydrocephalus, which was successfully managed with endoscopic third ventriculostomy (n=8) or VP shunt (n=1). Neuropathology confirmed 9 grade II astrocytoma and 3 pilocytic astrocytomas. 3 patients subsequently received radiotherapy and 2 received chemoradiotherapy for radiological progression since diagnosis. All patients remain alive with a median follow up of 9.5 years. 27 patients had a radiological diagnosis of presumed tectal plate glioma. Average age at diagnosis was 32 years with 80% (21/27) presenting with hydrocephalus. 2 patients underwent stereotactic needle biopsy but the tissue obtained was inconclusive, one of these patients received interstitial radiotherapy at the time of biopsy. During a median follow up of 8 years one patient died of unrelated causes while all other patients remain well. Of the 39 suspected tectal plate gliomas in our series 9 (23%) showed some radiological progression over a median 9 year follow up. Surgery was undertaken in 2 patients, chemotherapy in 1 and radiotherapy in 1 at time of progression, the other 5 patients remain under radiological surveillance CONCLUSION: Tectal plate glioma is a rare tumour in adults that usually presents with hydrocephalus requiring CSF diversion. The majority of these tumours are grade II astrocytoma or grade I pilocytic astrocytoma. Approximately one quarter of patients progressed on radiological follow up. The natural history and course of tectal plate glioma is therefore not entirely benign and patients should remain under close annual MRI surveillance with consideration of biopsy if radiological progression is observed.
Cocultures of Umbilical Cord Blood Hematopoietic Progenitor Cells and Umbilical Cord Endothelium.
Authors: Anja Moldenhauer, Lisa Selders, Gesche Genter, T. Hieronymus, D. Ruau, Andreas Lun, Matthias Futschik, Holger Kiesewetter, Martin Zenke, Abdulgabar Salama
Journal: Blood (2005)